Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Buy” from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average recommendation of “Buy” from the twelve research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $89.90.

Several analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partners lifted their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Scotiabank boosted their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 4th. HC Wainwright raised their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Finally, UBS Group started coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price on the stock.

Insider Activity

In other news, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the stock in a transaction on Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the transaction, the insider now directly owns 6,887 shares of the company’s stock, valued at $318,454.88. This represents a 12.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $46.31, for a total value of $1,157,750.00. Following the completion of the transaction, the chief executive officer now directly owns 307,054 shares in the company, valued at $14,219,670.74. The trade was a 7.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 192,032 shares of company stock worth $9,512,515 over the last three months. 29.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Janux Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Plato Investment Management Ltd boosted its stake in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the last quarter. Amalgamated Bank increased its position in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares during the last quarter. Summit Securities Group LLC purchased a new stake in Janux Therapeutics in the 2nd quarter worth about $29,000. Finally, Virtu Financial LLC raised its holdings in shares of Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after buying an additional 2,419 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Up 0.1 %

Janux Therapeutics stock opened at $56.83 on Friday. Janux Therapeutics has a 1-year low of $7.79 and a 1-year high of $71.71. The firm has a market cap of $2.98 billion, a P/E ratio of -48.57 and a beta of 3.29. The firm has a 50-day moving average of $53.89 and a 200-day moving average of $47.06.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. The company’s quarterly revenue was down 82.6% on a year-over-year basis. Research analysts forecast that Janux Therapeutics will post -1.35 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.